5 things to know about CRISPR and gene editing in the COVID era
Precision medicine is playing a key role in understanding COVID-19. Here's how gene testing and gene editing are accelerating the future of healthcare.
Mammoth Biosciences is a biotech company that has developed the world’s first and only CRISPR-based detection platform capable of sensing any biomarker or disease with DNA/RNA. CRISPR pioneer Jennifer Doudna and Trevor Martin, Ashley Tehranchi, Janice Chen and Lucas Harrington co-founded the company. Mammoth is on a mission to leverage the power of CRISPR to democratize disease detection by bringing accurate and affordable testing out of the laboratory and into the point of care. The company has raised nearly $25 million in funding from investors including Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos and Boom Capital.